

Lionbridge Publishes New eBook: 'Al and Language Strategy in Life Sciences'

eBook explores developing compliant, secure, Al-powered language strategy

WALTHAM, MA, UNITED STATES,
September 10, 2024 /
EINPresswire.com/ -- <u>Lionbridge</u>, a
global leader in translation and
localization solutions, has published a
new eBook, <u>"Al and Language Strategy</u>
in <u>Life Sciences."</u> This comprehensive
guide explores the transformative
impact of artificial intelligence (AI) on
language outcomes within the Life
Sciences industry. It provides the latest
guidance for safely embracing AI to



Discover how to bridge the trust gap and prepare to implement Al-powered language translation safely and effectively.

enhance language capabilities across the drug and medical device lifecycle.

Life Sciences companies are adopting AI, but are understandably cautious about trusting Large Language Models (LLMs) and AI to translate regulated content. Lionbridge's eBook addresses



As a leader in life sciences language services,
Lionbridge is at the forefront of understanding how new language technologies are transforming the industry."

Pia Windelov, VP Life Sciences
Strategy and Product
Marketing

how to achieve trust and control when deploying Alpowered language services. It also offers guidance on where and how LLMs can be utilized for cost efficiency without compromising language quality and compliance.

Authored by industry experts Pia Windelov, Vice President of Life Sciences Strategy and Product Marketing at Lionbridge, and Camilla de Villiers, Managing Director of Life Sciences at Lionbridge, the eBook bridges the trust gap and clarifies potential applications of LLMs to produce reliable language outcomes.

"As a leader in life sciences language services, Lionbridge is

at the forefront of understanding how new language technologies are transforming the industry," said de Villiers. "We help customers navigate this change by providing guidance on

safe, effective use of LLMs — even for highly regulated content."

Lionbridge Life Sciences is known for its subject-matter expertise, translation quality, and support for every touchpoint on the go-to-market drug and medical device journey that helps customers achieve their goals and reduce risk. Lionbridge's Life Sciences team relies on extensive experience in global clinical and regulatory translations, linguistic validation, life sciences marketing, and more. They ensure translations are clear, accurate, on time, and in compliance across all languages, markets, and cultures.

"In our eBook, we encourage our customers to take a risk-based approach to AI and define a product lifecycle language strategy that will result in exponential savings, language consistency, and faster time to market," said Windelov. "The volumes, repetitions, and interdependence across content throughout the lifecycle of a medicinal drug or medical device should propel companies to think more strategically about their content and language outcomes."

Read the eBook to discover how to bridge the trust gap and prepare to implement AI-powered language translation safely and effectively — even for regulated content.

Find "Al and Language Strategy in Life Sciences" <u>here</u>. For more information, visit: <u>https://www.lionbridge.com/life-sciences</u>.

About Lionbridge

Lionbridge partners with customers to break barriers and build bridges all over the world. For over 25 years, we have helped companies connect with their global customers and employees by delivering translation and localization solutions in 350+ languages. Through our world-class platform, we orchestrate a network of passionate experts across the globe who partner with brands to create culturally rich experiences. Relentless in our love of linguistics, we use the best of human and machine intelligence to forge connections with our customers' clients. Based in Waltham, Massachusetts, Lionbridge maintains solution centers in 24 countries. Learn more at www.lionbridge.com.

Andie Levine Lionbridge Technologies, LLC mediainquiries@lionbridge.com Visit us on social media:

Χ

LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/741986916
EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable

in today's world. Please see our Editorial Guidelines for more information. © 1995-2024 Newsmatics Inc. All Right Reserved.